Document ID: chunk:federal_register_of_legislation:F2024C01228:reg:105
Version: federal_register_of_legislation:F2024C01228
Segment Type: reg
Provision Reference: reg 105
Character Range: 46089–48136

105   Vaccine                                                                                                                                                                                                                                                                                Menitorix          Refrigerated lyophilised preparation for injection (0.5mL) with separate diluent  Each of the following :                                                                                                                                                                                                                                                                                                                                        1 dose
      Haemophilus influenzae type b (Hib) and Meningococcal C                                                                                                                                                                                                                                                                                                                                     (a) Hib capsular polysaccharide conjugated to tetanus toxoid‑ 5 µg
                                                                                                                                                                                                                                                                                                                                                                                                  (b) Group C meningococcal polysaccharide conjugated to tetanus toxoid‑ 5 µg
      Circumstances
      Vaccine may be provided to:
       (a) to a child who is about 12 months old; or
       (b) a person who is undergoing treatment, or will commence treatment, with Empavali (pegcetacoplan) for the treatment of adults with paroxysmal nocturnal haemoglobinuria who have inadequate an clinical response or are intolerant to treatment with eculizumab or ravulizumab.